Why the study?
Does atenolol improve Type A behavior pattern and cardiovascular reactivity in white, male hypertensive patients?
Does atenolol improve Type A behavior pattern and cardiovascular reactivity in white, male hypertensive patients?
Atenolol therapy may attenuate cardiovascular reactivity and shift Type A behavior toward Type B in hypertensive men.
Answers are grounded in this paper and cite their sources.
Supports beta-blocker use to shift Type A toward B and reduce reactivity in hypertensive men; extends benefits to behavioral domains in RCTs.
The influence of beta blockers on Type A behavior pattern and cardiovascular reactivity was tested. Nineteen white, male hypertensive patients were divided at random into two therapeutic groups (100 mg atenolol versus 50 mg hydrochlorothiazide + 5 mg amiloride (control group) ). For each patient, the German version of the structured interview was performed before therapy and at a minimum of 4 weeks after normalization of clinical resting casual blood pressure (BP). Prior to therapy, there were no differences in age, BP at rest, cardiovascular reactivity, and Type A between the two groups. After therapy, the patients treated with beta blockers changed Type A characteristics toward Type B, regardless where they started on the Type A scale, and beta blockers attenuated cardiovascular reactivity. In this study, Type A (hypertensive patients) was not associated with greater cardiovascular reactivity.
No takes yet. Share an insight, caveat, or question.
Schmieder et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: